Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, Tao-Yuan, Taiwan; Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan, Taiwan.
Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Tao-Yuan, Taiwan.
Taiwan J Obstet Gynecol. 2019 Sep;58(5):662-666. doi: 10.1016/j.tjog.2019.07.014.
Prenatal diagnosis of de novo segmental amplification or deletion by microarray-based comparative genomic hybridization (array CGH) is uncommon. The study aimed to know about the incidence, abnormal ultrasound findings, and pregnancy outcomes of prenatally diagnosed de novo segmental amplification or deletion by array CGH.
Between January 2014 and December 2017, we analyzed pregnant women who received prenatal array CGH (SurePrint G3 Human CGH Microarray Kit, 8 × 60K) at Chang Gung Memorial Hospital, Taiwan. Clinical data on maternal age, reason for fetal karyotyping, sonographic findings, gestational age at delivery, newborn birth weight, and associated anomalies, if any, were obtained by chart review.
A total of 836 specimens (814 amniotic fluid samples, 4 cord blood samples, 18 chorionic villi samples) were analyzed by array CGH during the study period. Of the 56 cases with abnormal array CGH results, 40 had segmental amplification or deletion, 12 had trisomy, three had monosomy, and one had sex chromosome aneuploidy. Of these 40 cases with segmental amplification or deletion, 30 were inherited and 10 were de novo occurrences. The incidence of de novo segmental amplification or deletion was 1.2% (10/836). Abnormal prenatal ultrasound findings occurred in 40% (4/10) of de novo segmental amplification or deletion cases. Among these 10 pregnancies, nine were voluntarily terminated between 22 and 26 weeks of gestation and one was delivered at term.
Prenatal diagnosis of de novo segmental amplification or deletion by array CGH raises important genetic counseling issues. In our series, the incidence of de novo segmental amplification or deletion in prenatal samples was 1.2%. Abnormal prenatal sonographic findings occurred in 40% of these de novo segmental amplification or deletion cases. Of these de novo segmental amplification or deletion pregnancies, 90% were voluntarily terminated.
通过基于微阵列的比较基因组杂交(array CGH)进行的新发片段扩增或缺失的产前诊断并不常见。本研究旨在了解通过 array CGH 产前诊断新发片段扩增或缺失的发生率、异常超声发现和妊娠结局。
2014 年 1 月至 2017 年 12 月期间,我们分析了在台湾长庚纪念医院接受产前 array CGH(SurePrint G3 人类 CGH 微阵列试剂盒,8×60K)检查的孕妇。通过病历回顾获得了母体年龄、胎儿核型分析的原因、超声发现、分娩时的胎龄、新生儿出生体重以及任何相关异常等临床数据。
研究期间,共对 836 个标本(814 个羊水样本、4 个脐血样本、18 个绒毛样本)进行了 array CGH 分析。在 56 例异常 array CGH 结果中,有 40 例存在片段扩增或缺失,12 例存在三体性,3 例存在单体性,1 例存在性染色体非整倍性。在这 40 例片段扩增或缺失病例中,有 30 例为遗传性,10 例为新发病例。新发片段扩增或缺失的发生率为 1.2%(10/836)。新发片段扩增或缺失病例中,40%(4/10)存在异常产前超声发现。在这 10 例妊娠中,有 9 例在 22 至 26 周时自愿终止妊娠,有 1 例足月分娩。
通过 array CGH 对新发片段扩增或缺失的产前诊断引发了重要的遗传咨询问题。在我们的研究中,产前样本中新发片段扩增或缺失的发生率为 1.2%。在这些新发片段扩增或缺失病例中,40%存在异常产前超声发现。在这些新发片段扩增或缺失的妊娠中,90%被自愿终止。